/PRNewswire/ Sumitomo Pharma Canada, Inc., announced today that ORGOVYX® (relugolix), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, is.
European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.